



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Brown et al.) Group Art Unit 1635
App. No. : 09 931,732)
Filed : August 16, 2001)
For : ANTISENSE OLIGONUCLEOTIDES)
COMPRISING UNIVERSAL AND OR)
DEGENERATE BASE)
Examiner : J. Epps

TECH CENTER 1600/1500

RECEIVED

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 8/14/02

By: Eric S. Furman
Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550



PATENT

Case Docket No. OASBIO.00101

Date: August 14, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Brown et al.

Appl. No. : 09 931,732

Filed : August 16, 2001

For : ANTISENSE
OLIGONUCLEOTIDES
COMPRISING UNIVERSAL
AND/OR DEGENERATE BASE

Examiner : J. Epps

Group Art Unit : 1635

) I hereby certify that this correspondence and all
) marked attachments are being deposited with the
) United States Postal Service as first class mail in
) an envelope addressed to: United States Patent
) and Trademark Office, P.O. Box 2327,
) Arlington VA 22202, on

August 14, 2002

(Date)

Eric S. Furman, Ph.D., Reg. No. 45,664

TRANSMITTAL LETTER

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:


- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with one hundred four (109) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
OASB:O.001C1APPLICATION NO.
09/931,732INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE FOR SEVERAL SHEETS IF NECESSARY)

APPLICANT
Brown et al.FILING DATE
August 16, 2001GROUP
1635

RECEIVED
 AUG 29 2001
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE E. APPROPRIATE
	1	4,458,066	07/03/84	Caruthers et al.		
	2	4,683,194	07/28/87	Saiki et al.		
	3	5,104,792	04/14/92	Silver et al.		
	4	5,112,974	05/12/92	Barton		
	5	5,223,618	06/29/93	Cook et al.		
	6	5,378,825	01/03/95	Cook et al.		
	7	5,424,413	06/13/95	Hogan et al.		
	8	5,438,131	08/01/95	Bergstrom et al.		
	9	5,451,503	09/19/95	Hogan et al.		
	10	5,489,677	02/06/96	Sanghvi et al.		
	11	5,539,082	07/23/96	Nielsen et al.		
	12	5,541,307	07/30/96	Cook et al.		
	13	5,571,902	11/05/96	Ravikumar et al.		
	14	5,571,903	11/05/96	Gryaznov		
	15	5,583,032	12/10/96	Torrence et al.		
	16	5,612,199	03/18/97	Western et al.		
	17	5,612,215	03/18/97	Draper et al.		
	18	5,627,032	05/06/97	Ulanovsky		
	19	5,650,271	07/22/97	Richards		
	20	5,677,289	10/14/97	Torrence et al.		
	21	5,681,702	10/28/97	Collins et al.		
	22	5,681,947	10/28/97	Bergstrom et al.		
	23	5,683,879	11/04/97	Laney et al.		
	24	5,686,242	11/11/97	Bruice et al.		
	25	5,700,922	12/23/97	Cook		
	26	5,719,271	02/17/98	Cook et al.		
	27	5,728,818	03/17/98	Wincott et al.		
	28	5,780,233	07/14/98	Guo et al.		
	29	5,780,610	07/14/98	Collins et al.		
	30	5,840,845	11/24/98	Smith et al.		

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
OASEIO.001C1APPLICATION NO.
09/931,732

TECH CENTER 1600/2900

AUG 20 2002

RECEIVED

AUG 28 2002

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Brown et al.FILING DATE
August 16, 2001GROUP
1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	31	5,843,650	12/01/98	Segev			
	32	5,877,162	03/02/99	Werner et al.			
	33	5,942,657	08/24/99	Bird et al.			
	34	5,952,202	09/14/99	Aoyagi et al.			
	35	5,968,748	10/19/99	Bennett et al.			
	36	5,981,179	11/09/99	Lorinez et al.			
	37	6,025,130	02/15/00	Thomas et al.			
	38	6,027,893	02/22/00	Ørum et al.			
	39	6,037,130	03/14/00	Tyagi et al.			
	40	6,084,102	07/04/00	Kutyavin et al.			
	41	6,133,031	10/17/00	Monia et al.			
	42	6,150,141	11/21/00	Jarrell			
	43	6,159,694	12/12/00	Karras			
	44	6,194,158	02/27/01	Kroes et al.			
	45	6,201,107	03/13/01	Lap-Chee et al.			
	46	6,228,642	05/08/01	Baker et al.			
	47	6,232,079	05/15/01	Wittwer et al.			
	48	6,232,462	03/15/01	Collins et al.			
	49	6,346,614	02/12/02	Metelev et al.			
	50	6,361,940	03/26/02	Van Ness et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	51	WO 89/02921	04/06/89	Patent Cooperation Treaty				
	52	WO 91/15601	10/17/91	Patent Cooperation Treaty				
	53	WO 93/05175	03/18/93	Patent Cooperation Treaty				
	54	WO 93/05176	03/18/93	Patent Cooperation Treaty				
	55	WO 93/23551	11/25/93	Patent Cooperation Treaty				
	56	WO 96/32474	10/17/96	Patent Cooperation Treaty				

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
OAS&IO.001C1APPLICATION NO.
09/931,732INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Brown et al.FILING DATE
August 16, 2001GROUP
1635

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	57	WO 97/28177	08/07/97	Patent Cooperation Treaty				
	58	WO 97/38097	10/16/97	Patent Cooperation Treaty				
	59	WO 97/46711	12/11/97	Patent Cooperation Treaty				
	60	WO 99/13886	03/25/99	Patent Cooperation Treaty				
	61	WO 99/18238	04/15/99	Patent Cooperation Treaty				
	62	WO 00/61810	10/19/00	Patent Cooperation Treaty				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	63	Chemical Abstracts and Indexes, American Chemical Society, Columbus, US. XP000376987. ISSN: 0009-2258. (1990).
	64	Amosova et al. "Effect of the 1-(2'-deoxy-Beta-D-ribofuranosyl)-3-Nitropyrrole Residue on the Stability of DNA Duplexes and Triplexes," <i>Nucleic Acids Research</i> , 25(10):1930-1934 (1997).
	65	Benseler et al., "Hammerhead-like Molecules Containing NonNucleotide Linkers are Active RNA Catalysts," <i>J. Am. Chem. Soc.</i> , 115:8483-8484, (1993).
	66	Bergstrom et al., "Synthesis, Structure, and Deoxyribonucleic Acid Sequencing with a Universal Nucleoside: 1-(2'-Deoxy-β-D-Ribofuranosyl)-3-nitropyrrole," <i>J. Am. Chem. Soc.</i> , 117:1201-1209 (1995).
	67	Blommers et al. "Effects of the Introduction of L-Nucleotides into DNA. Solution Structure of the Heterochiral Duplex d(G-C-G-(L)T-G-C-G) d(C-G-C-A-C-G-C) Studied by NMR Spectroscopy," <i>Biochemistry</i> , 33:1886-1896 (1994)
	68	Bolufer et al. "Rapid Quantative Detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes," <i>Haematologica</i> , 85(12):1248-1254 (2000).
	69	Brown et al., "Synthesis and duplex stability of oligonucleotides containing adenine-guanine analogues," <i>Carbohydrate Res</i> , 216:129-139 (1991).
	70	Chen et al., "Synthesis of Oligodeoxyribonucleotide N3'-P5' Phosphoramidates," <i>Nucleic Acids Research</i> , 23(14):2661-2668 (1995).
	71	Chiang et al., "Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms," <i>J. Biol. Chem.</i> , 266(27):18162-18171 (1991).
	72	Devaney et al. "Genotyping of two mutations in the HFE gene using single-base extension and high-performance liquid chromatography," <i>Anal. Chem.</i> , 73(3): 620-624 (2001).
	73	Donohue et al., "Rapid single-tube screening of the C282Y hemochromatosis mutation by real-time multiplex allele-specific PCR without fluorescent probes," <i>Clinical Chemistry</i> , 46(10):1540-1547 (2000).
	74	Dueholm et al., "Synthesis of Peptide Nucleic Acid Monomers Containing the Four Natural Nucleobases: Thymine, Cytosine, Adenine, and Guanine and their Oligomerization," <i>J Org. Chem.</i> , 59:5767-5773 (1994).
	75	Eritja et al., "Synthesis and properties of defined DNA oligomers containing base mispairs involving 2-aminopurine," <i>Nucleic Acids Research</i> , 14(14):5869-5884 (1986).
	76	Frutos et al. "Method for Detection of Single-Base Mismatches Using Bimolecular Beacons," <i>J. Am. Chem. Soc.</i> , 124(11):2396-2397 (Received for publication 10/16/01) Published 2/26/2002 .
	77	Guttridge et al. "Population Screening for Hemochromatosis by PCR Using Sequence-Specific Primers," <i>Genetic Testing</i> , 4(2):111-114 (2000).
	78	Hartmann et al., "Specific suppression of human tumor necrosis factor-α synthesis by antisense oligodeoxynucleotides," <i>Antisense and Nucleic Acid Drug Development</i> , 6:291-299 (1996).

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
OASEIO.001C1APPLICATION NO.
09/931,732INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Brown et al.FILING DATE
August 16, 2001GROUP
1635

(SEE SEVERAL SHEETS IF NECESSARY)

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- 79 Heim et al., "Highly sensitive detection of gene expression of an intronless gene: amplification of mRNA, but not genomic DNA by nucleic acid sequence based amplification (NASBA)," *Nucleic Acids Research*, 26(9):2250-2251 (1998).
- 80 Hendry et al. "Using Linkers to Investigate the Spatial Separation of the Conserved Nucleotides A9 and G12 in the Hammerhead Ribozyme," *Biochimica et Biophysica Acta*, 1219(2):405-412 (1994).
- 81 Izant and Weintraub, "Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis," *Cell*, 36:1007-1015 (1984).
- 82 Krupp G., "Antisense Oligoribonucleotides and RNase P. A Great Potential," *Biochimie* 75(1/2):135-139 (1993).
- 83 Kunitsyn et al. "Stabilizing Effect of 5-Nitroindole (Universal Base) on DNA Duplexes Immobilized on Gel Matrix," *J. of Biomolec. Structure and Dynamics*, 15(3):597-603 (1997).
- 84 Lieber et al. "Selection of Efficient Cleavage Sites in Target RNAs by Using a Ribozyme Expression Library," *Molecule and Cellular Biology*, 15(1):540-551 (1995).
- 85 Lin and Brown, "Synthesis and duplex stability of oligonucleotides containing cystosine-thymine analogues," *Nucleic Acids Research*, 17(24):10373-10383 (1989).
- 86 Lin and Brown, "Synthesis of oligodeoxyribonucleotides containing degenerate bases and their use as primers in the polymerase chain reaction," *Nucleic Acids Research*, 20(19):5149-5152 (1992).
- 87 Lizardi et al., "Mutation detection and single-molecule counting using isothermal rolling-circle amplification," *Nature Genet.*, 19:225-232 (1998).
- 88 Loakes, "3-Nitropyrrole and 5-Nitroindole as Universal Bases in Primers for DNA Sequencing and PCR," *Nucleic Acids Research*, 23(13):2361-2366 (1995).
- 89 Ma et al., "Nuclease-resistant external guide sequence-induced cleavage of target RNA by human ribonuclease P," *Antisense and Nucleic Acid Drug Development*, 8:415-426 (1998).
- 90 McCurdy et al., "An Improved Method for the Synthesis of N3'-P5' Phosphoramidate Oligonucleotides," *Tetrahedron Lett*, 38(2):207-210 (1997).
- 91 Medintz et al. "High speed single nucleotide polymorphism typing of a hereditary haemochromatosis mutation with capillary array electrophoresis microplates," *Electrophoresis*, 21:2352-2358 (2000).
- 92 Milligan et al. "Current Concepts in Antisense Drug Design" *J. Medicinal Chemistry*, 36(14):1923-1937 (1993).
- 93 Morvan et al., "Oligonucleotide Mimics for Antisense Therapeutics: Solution Phase and Automated Solid-Support Synthesis of MMI Linked Oligomers," *J Am Chem Soc*, 118:255-256 (1996).
- 94 Mueller et al., "Self-sustained sequence replication (3SR): an alternative to PCR," *Histochem Cell Biol*, 108:431-437 (1997).
- 95 Nelson et al., "N3'-P5' Oligodeoxyribonucleotide Phosphoramidates: A New Method of Synthesis Based on a Phosphoramidite Amine-Exchange Reaction," *J. Org. Chem.*, 62:7278-7287 (1997).
- 96 Nichols et al., "A Universal Nucleoside for Use at Ambiguous Sites in DNA Primers" *Nature*, 369:492-493 (1994).
- 97 Perbost et al., "Synthesis of 5'-O-Amino-2'-deoxypyrimidine and Purine Nucleosides: Building Blocks for Antisense Oligonucleotides," *J. Org. Chem.*, 60:5150-5156 (1995).
- 98 Pierce et al. "Construction of a Directed Hammerhead Ribozyme Library: Towards the Identification of Optimal Target Sites for Antisense-Mediated Gene Inhibition," *Nucleic Acids Research*, 26(22):5093-5101 (1998).
- 99 Pitsch et al., "Why Pentose and Not Hexose-Nucleic Acids?" *Helv Chimica Acta*, 76:2161-2183 (1993).
- 100 Press, R., "Detection of Prevalent Genetic Alterations Predisposing to Hemochromatosis and Other Common Human Diseases," *Clinical Chem*, 46:1526-1527 (2000).
- 101 Restagno et al. "A Pilot C282Y Hemochromatosis Screening in Italian Newborns by TaqMan (TM) Technology," *Genetic Testing*, 4(2):177-181 (2000).
- 102 Reynolds et al. "Antisense Oligonucleotides Containing an Internal, Non-nucleotide-based Linker Promote Site-Specific Cleavage of RNA," *Nucleic Acids Research*, 24(4):760-765 (1996).
- 103 Romano et al., "NASBA technology: isothermal RNA amplification in qualitative and quantitative diagnostics," *Immunol. Invest.*, 26:15-28 (1997).

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
OAS2IC.001C1APPLICATION NO.
09/931,732INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

USE SEVERAL SHEETS IF NECESSARY.

APPLICANT
Brown et al.FILING DATE
August 16, 2001GROUP
1635

RECEIVED

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- | | |
|-----|---|
| 104 | Spargo et al., "Detection of <i>M. tuberculosis</i> DNA using thermophilic strand displacement amplification." <i>Mol. Cell Probes</i> , 10:247-256 (1996). |
| 105 | Swayze et al., "The Synthesis of N,N'-O-Trisubstituted Hydroxylamines via a Mild Reductive Alkylation Procedure: An Improved Synthesis of the MMI Backbone," <i>Synlett</i> , pp. 859-861 (1997). |
| 106 | Van Aerschot et al., "An Acyclic 5-Nitroindazole Nucleoside Analogue as Ambiguous Nucleoside," <i>Nucleic Acids Research</i> , 23(21):4363-4370 (1995). |
| 107 | Walker, "Empirical aspects of strand displacement amplification," <i>PCR Methods Applications</i> , 3:1-6 (1993). |
| 108 | Zhong and Kallenbach, "Conformation and Thermodynamics of DNA 'Necks' Models for Three-arm Branch Formation in a Duplex," <i>J. Mol. Biol.</i> , 230:766-778 (1993). |
| 109 | Zhong et al., "Effects of Unpaired Bases on the Conformation and Stability of Three-Arm DNA Junctions," <i>Biochemistry</i> , 33:3660-3667 (1994). |

S:\DOCS\ESF\ESF-5454.DOC
081202

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT